Soheil Meshinchi, MD, PhD

Soheil Meshinchi, MD, PhD

Specialties

  • Biography

    Soheil Meshinchi, MD, PhD, is attending physician at Seattle Children’s Hospital, associate professor at the University of Washington School of Medicine and associate member of Fred Hutchinson Cancer Research Center (FHCRC). He attends on the Hematopoietic Stem Cell Transplant Service. He is co-director of the COG Myeloid Resource Laboratory, chairman of the COG Myeloid Disease Biology Committee, Vice chair of the COG Myeloid Disease committee and the Biology chair and vice chair of the COG acute myeloid leukemia (AML) phase III trial.

    In addition, he serves on several COG committees, including the committee for development of new APL therapy, phase III AML committee, phase II trial of STI571 for Philadelphia chromosome leukemias and the infant leukemia steering committee. Dr. Meshinchi’s clinical and research interests center around the treatment of pediatric myeloid leukemia. He is principal investigator on ten research projects at FHCRC and Seattle Children’s, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification. He supervises the treatment and management of all patients with myeloid diseases (AML, MDS, etc.) in the Seattle Cancer Care Alliance, and he is working to identify novel therapies in AML.

    Education

    University of Michigan--Ann Arbor, Ann Arbor, MI
    Wayne State University School of Medicine, Detroit, MI

    Fellowship

    University of Washington School of Medicine, Seattle, WA
    Wilmer Eye Institute-Johns Hopkins University, Baltimore, MD

    Research Description

    My clinical and research interests center around the treatment of pediatric myeloid leukemia. I am principal investigator on six research projects at Seattle Children's and Fred Hutchinson Cancer Research Center, including a study on the biology of the alterations of the signal transduction pathway in pediatric cancers, the biology and prognostic implications of FLT3 mutations in AML and the evaluation of minimal residual disease by multiparameter flow cytometry for risk identification.

    Research Focus Area

    Cancer, Novel Therapeutics, Refractory and recurrent cancer, Sarcomas, Thyroid Cancer

  • Related Resources

  • Patient Testimonials

    • {{ testimonial.displayName }}
      {{ testimonial.location }}
      {{ formatTestimonialDate(testimonial.date) }}

      {{ testimonial.testimony }}

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }}

  • Publications

  • Presentations

    Presentation Title Event Location Date
    {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }}

  • Research Funding

    Grant Title Grantor Amount Award Date
    {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }}

  • Clinical Trials and Research

    {{ item.t }}

    {{ item.st }}

    {{ item.obj }}

    Condition: {{ item.con }} Phase: {{ item.ph }} Clinicaltrials.gov ID: {{ item.nct }}

    No clinical trials found for Soheil Meshinchi, MD, PhD.